{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:23:21Z","timestamp":1792801401587,"version":"4.5.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-024-00804-0","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T17:02:55Z","timestamp":1729702975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A review of temporal interference, nanoparticles, ultrasound, gene therapy, and designer receptors for Parkinson disease"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-8253","authenticated-orcid":false,"given":"A. D.","family":"Currie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4632-3417","authenticated-orcid":false,"given":"J. K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6247-9358","authenticated-orcid":false,"given":"M. S.","family":"Okun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"804_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.776847","volume":"9","author":"Z Ou","year":"2021","unstructured":"Ou, Z. et al. Global trends in the incidence, prevalence, and years lived with disability of Parkinson\u2019s disease in 204 countries\/territories from 1990 to 2019. Front. Public Health 9, 776847 (2021).","journal-title":"Front. Public Health"},{"key":"804_CR2","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"804_CR3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira, A. H. V., Chaudhuri, K. R. & Jenner, P. Non-motor features of Parkinson disease. Nat. Rev. Neurosci. 18, 435\u2013450 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"804_CR4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong, M. J. & Okun, M. S. Diagnosis and treatment of Parkinson disease: a review. JAMA 323, 548\u2013560 (2020).","journal-title":"JAMA"},{"key":"804_CR5","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","volume":"97","author":"T Pringsheim","year":"2021","unstructured":"Pringsheim, T. et al. Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: a report of the AAN guideline subcommittee. Neurology 97, 942\u2013957 (2021).","journal-title":"Neurology"},{"key":"804_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1177\/0306312713483678","volume":"43","author":"J Gardner","year":"2013","unstructured":"Gardner, J. A history of deep brain stimulation: technological innovation and the role of clinical assessment tools. Soc. Stud. Sci. 43, 707\u2013728 (2013).","journal-title":"Soc. Stud. Sci."},{"key":"804_CR7","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1056\/NEJM199810153391603","volume":"339","author":"P Limousin","year":"1998","unstructured":"Limousin, P. et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson\u2019s disease. N. Engl. J. Med. 339, 1105\u20131111 (1998).","journal-title":"N. Engl. J. Med."},{"key":"804_CR8","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa060281","volume":"355","author":"G Deuschl","year":"2006","unstructured":"Deuschl, G. et al. A randomized trial of deep-brain stimulation for Parkinson\u2019s disease. N. Engl. J. Med. 355, 896\u2013908 (2006).","journal-title":"N. Engl. J. Med."},{"key":"804_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2008.929","volume":"301","author":"FM Weaver","year":"2009","unstructured":"Weaver, F. M. et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 301, 63\u201373 (2009).","journal-title":"JAMA"},{"key":"804_CR10","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1056\/NEJMoa000827","volume":"345","author":"Deep-Brain Stimulation for Parkinso","year":"2001","unstructured":"Deep-Brain Stimulation for Parkinson\u2019s Disease Study Group et al. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson\u2019s disease. N. Engl. J. Med 345, 956\u2013963 (2001).","journal-title":"N. Engl. J. Med"},{"key":"804_CR11","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/j.wneu.2022.10.034","volume":"171","author":"NP Rasiah","year":"2023","unstructured":"Rasiah, N. P., Maheshwary, R., Kwon, C.-S., Bloomstein, J. D. & Girgis, F. Complications of deep brain stimulation for Parkinson disease and relationship between micro-electrode tracks and hemorrhage: systematic review and meta-analysis. World Neurosurg. 171, e8\u2013e23 (2023).","journal-title":"World Neurosurg."},{"key":"804_CR12","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1001\/jamaneurol.2017.3098","volume":"74","author":"AE Bond","year":"2017","unstructured":"Bond, A. E. et al. Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant Parkinson disease: a randomized clinical trial. JAMA Neurol. 74, 1412 (2017).","journal-title":"JAMA Neurol."},{"key":"804_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S1474-4422(17)30403-9","volume":"17","author":"R Mart\u00ednez-Fern\u00e1ndez","year":"2018","unstructured":"Mart\u00ednez-Fern\u00e1ndez, R. et al. Focused ultrasound subthalamotomy in patients with asymmetric Parkinson\u2019s disease: a pilot study. Lancet Neurol. 17, 54\u201363 (2018).","journal-title":"Lancet Neurol."},{"key":"804_CR14","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1056\/NEJMoa2016311","volume":"383","author":"R Mart\u00ednez-Fern\u00e1ndez","year":"2020","unstructured":"Mart\u00ednez-Fern\u00e1ndez, R. et al. Randomized trial of focused ultrasound subthalamotomy for Parkinson\u2019s disease. N. Engl. J. Med. 383, 2501\u20132513 (2020).","journal-title":"N. Engl. J. Med."},{"key":"804_CR15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2202721","volume":"388","author":"V Krishna","year":"2023","unstructured":"Krishna, V. et al. Trial of Globus Pallidus focused ultrasound ablation in Parkinson\u2019s disease. N. Engl. J. Med 388, 683\u2013693 (2023).","journal-title":"N. Engl. J. Med"},{"key":"804_CR16","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.cell.2017.05.024","volume":"169","author":"N Grossman","year":"2017","unstructured":"Grossman, N. et al. Noninvasive deep brain stimulation via temporally interfering electric fields. Cell 169, 1029\u20131041.e16 (2017).","journal-title":"Cell"},{"key":"804_CR17","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/S1474-4422(17)30224-7","volume":"16","author":"A Gunduz","year":"2017","unstructured":"Gunduz, A. & Okun, M. S. A new non-surgical approach for deep-brain stimulation. Lancet Neurol. 16, e1 (2017).","journal-title":"Lancet Neurol."},{"key":"804_CR18","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41593-023-01456-8","volume":"26","author":"IR Violante","year":"2023","unstructured":"Violante, I. R. et al. Non-invasive temporal interference electrical stimulation of the human hippocampus. Nat. Neurosci. 26, 1994\u20132004 (2023).","journal-title":"Nat. Neurosci."},{"key":"804_CR19","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1038\/s41593-023-01457-7","volume":"26","author":"MJ Wessel","year":"2023","unstructured":"Wessel, M. J. et al. Noninvasive theta-burst stimulation of the human striatum enhances striatal activity and motor skill learning. Nat. Neurosci. 26, 2005\u20132016 (2023).","journal-title":"Nat. Neurosci."},{"key":"804_CR20","unstructured":"Wang, Y., Qu, W. & Choi, S. FDA\u2019s regulatory science program for generic PLA\/ PLGA-based drug products. https:\/\/www.americanpharmaceuticalreview.com\/Featured-Articles\/188841-FDA-s-Regulatory-Science-Program-for-Generic-PLA-PLGA-Based-Drug-Products\/ (2016)."},{"key":"804_CR21","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1021\/nn506408v","volume":"9","author":"R Pahuja","year":"2015","unstructured":"Pahuja, R. et al. Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in Parkinsonian rats. ACS Nano 9, 4850\u20134871 (2015).","journal-title":"ACS Nano"},{"key":"804_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-94175-8","volume":"11","author":"V Monge-Fuentes","year":"2021","unstructured":"Monge-Fuentes, V. et al. Dopamine-loaded nanoparticle systems circumvent the blood\u2013brain barrier restoring motor function in mouse model for Parkinson\u2019s Disease. Sci. Rep. 11, 15185 (2021).","journal-title":"Sci. Rep."},{"key":"804_CR23","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1080\/10717544.2019.1636420","volume":"26","author":"S Tang","year":"2019","unstructured":"Tang, S. et al. Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson\u2019s disease. Drug Deliv. 26, 700\u2013707 (2019).","journal-title":"Drug Deliv."},{"key":"804_CR24","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/10837450.2020.1740257","volume":"25","author":"S Arisoy","year":"2020","unstructured":"Arisoy, S. et al. In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery. Pharm. Dev. Technol. 25, 735\u2013747 (2020).","journal-title":"Pharm. Dev. Technol."},{"key":"804_CR25","doi-asserted-by":"publisher","first-page":"6070","DOI":"10.3390\/ijms21176070","volume":"21","author":"TM Sim","year":"2020","unstructured":"Sim, T. M., Tarini, D., Dheen, S. T., Bay, B. H. & Srinivasan, D. K. Nanoparticle-based technology approaches to the management of neurological disorders. Int. J. Mol. Sci. 21, 6070 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"804_CR26","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0301-5629(99)00062-9","volume":"25","author":"P Dayton","year":"1999","unstructured":"Dayton, P., Klibanov, A., Brandenburger, G. & Ferrara, K. Acoustic radiation force in vivo: a mechanism to assist targeting of microbubbles. Ultrasound Med. Biol. 25, 1195\u20131201 (1999).","journal-title":"Ultrasound Med. Biol."},{"key":"804_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114539","volume":"190","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. Ultrasound-mediated blood\u2013brain barrier opening: an effective drug delivery system for theranostics of brain diseases. Adv. Drug Deliv. Rev. 190, 114539 (2022).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"804_CR28","doi-asserted-by":"publisher","first-page":"034301","DOI":"10.1103\/PhysRevLett.106.034301","volume":"106","author":"H Chen","year":"2011","unstructured":"Chen, H., Kreider, W., Brayman, A. A., Bailey, M. R. & Matula, T. J. Blood vessel deformations on microsecond time scales by ultrasonic cavitation. Phys. Rev. Lett. 106, 034301 (2011).","journal-title":"Phys. Rev. Lett."},{"key":"804_CR29","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.ultrasmedbio.2007.12.015","volume":"34","author":"N Sheikov","year":"2008","unstructured":"Sheikov, N., McDannold, N., Sharma, S. & Hynynen, K. Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium. Ultrasound Med. Biol. 34, 1093\u20131104 (2008).","journal-title":"Ultrasound Med. Biol."},{"key":"804_CR30","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.ultrasmedbio.2004.04.010","volume":"30","author":"N Sheikov","year":"2004","unstructured":"Sheikov, N., McDannold, N., Vykhodtseva, N., Jolesz, F. & Hynynen, K. Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med. Biol. 30, 979\u2013989 (2004).","journal-title":"Ultrasound Med. Biol."},{"key":"804_CR31","doi-asserted-by":"crossref","unstructured":"Zhong, Y.-X. et al. Low intensity focused ultrasound: a new prospect for the treatment of Parkinson\u2019s disease. Ann. Med. 55, 2251145 (2023).","DOI":"10.1080\/07853890.2023.2251145"},{"key":"804_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11060-021-03861-0","volume":"156","author":"Y Meng","year":"2022","unstructured":"Meng, Y. et al. Current state of therapeutic focused ultrasound applications in neuro-oncology. J. Neurooncol. 156, 49\u201359 (2022).","journal-title":"J. Neurooncol."},{"key":"804_CR33","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(23)00112-2","volume":"24","author":"AM Sonabend","year":"2023","unstructured":"Sonabend, A. M. et al. Repeated blood\u2013brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. Lancet Oncol. 24, 509\u2013522 (2023).","journal-title":"Lancet Oncol."},{"key":"804_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36340-0","volume":"9","author":"T Mainprize","year":"2019","unstructured":"Mainprize, T. et al. Blood-brain barrier opening in primary brain tumors with non-invasive MR-guided focused ultrasound: a clinical safety and feasibility study. Sci. Rep. 9, 321 (2019).","journal-title":"Sci. Rep."},{"key":"804_CR35","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3171\/2019.10.JNS192206","volume":"134","author":"SH Park","year":"2020","unstructured":"Park, S. H. et al. Safety and feasibility of multiple blood-brain barrier disruptions for the treatment of glioblastoma in patients undergoing standard adjuvant chemotherapy. J. Neurosurg. 134, 475\u2013483 (2020).","journal-title":"J. Neurosurg."},{"key":"804_CR36","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.3389\/fonc.2020.01663","volume":"10","author":"SH Park","year":"2020","unstructured":"Park, S. H. et al. One-year outcome of multiple blood-brain barrier disruptions with temozolomide for the treatment of glioblastoma. Front. Oncol. 10, 1663 (2020).","journal-title":"Front. Oncol."},{"key":"804_CR37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2103280118","volume":"118","author":"P Anastasiadis","year":"2021","unstructured":"Anastasiadis, P. et al. Localized blood\u2013brain barrier opening in infiltrating gliomas with MRI-guided acoustic emissions\u2013controlled focused ultrasound. Proc. Natl Acad. Sci. 118, e2103280118 (2021).","journal-title":"Proc. Natl Acad. Sci."},{"key":"804_CR38","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3171\/2022.9.JNS221565","volume":"139","author":"AR Rezai","year":"2022","unstructured":"Rezai, A. R. et al. Focused ultrasound\u2013mediated blood-brain barrier opening in Alzheimer\u2019s disease: long-term safety, imaging, and cognitive outcomes. J. Neurosurg. 139, 275\u2013283 (2022).","journal-title":"J. Neurosurg."},{"key":"804_CR39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1056\/NEJMoa2308719","volume":"390","author":"AR Rezai","year":"2024","unstructured":"Rezai, A. R. et al. Ultrasound blood\u2013brain barrier opening and aducanumab in Alzheimer\u2019s disease. N. Engl. J. Med. 390, 55\u201362 (2024).","journal-title":"N. Engl. J. Med."},{"key":"804_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04529-6","volume":"9","author":"N Lipsman","year":"2018","unstructured":"Lipsman, N. et al. Blood\u2013brain barrier opening in Alzheimer\u2019s disease using MR-guided focused ultrasound. Nat. Commun. 9, 2336 (2018).","journal-title":"Nat. Commun."},{"key":"804_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2020.593672","volume":"14","author":"P-F D\u2019Haese","year":"2020","unstructured":"D\u2019Haese, P.-F. et al. \u03b2-amyloid plaque reduction in the hippocampus after focused ultrasound-induced blood-brain barrier opening in Alzheimer\u2019s disease. Front. Hum. Neurosci. 14, 593672 (2020).","journal-title":"Front. Hum. Neurosci."},{"key":"804_CR42","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1002\/mds.29134","volume":"37","author":"JA Pineda-Pardo","year":"2022","unstructured":"Pineda-Pardo, J. A. et al. Striatal blood\u2013brain barrier opening in Parkinson\u2019s disease dementia: a pilot exploratory study. Mov. Disord. 37, 2057\u20132065 (2022).","journal-title":"Mov. Disord."},{"key":"804_CR43","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/mds.29190","volume":"37","author":"Y Meng","year":"2022","unstructured":"Meng, Y. et al. Putaminal recombinant glucocerebrosidase delivery with magnetic resonance\u2013guided focused ultrasound in Parkinson\u2019s disease: a phase I study. Mov. Disord. 37, 2134\u20132139 (2022).","journal-title":"Mov. Disord."},{"key":"804_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-40598-4","volume":"13","author":"L Xu","year":"2023","unstructured":"Xu, L., Gong, Y., Chien, C.-Y., Leuthardt, E. & Chen, H. Transcranial focused ultrasound-induced blood\u2012brain barrier opening in mice without shaving hairs. Sci. Rep. 13, 13500 (2023).","journal-title":"Sci. Rep."},{"key":"804_CR45","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel, H. et al. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain 146, 4414\u20134424 (2023).","journal-title":"Brain"},{"key":"804_CR46","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway, S. et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 79, 13\u201321 (2022).","journal-title":"JAMA Neurol."},{"key":"804_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med"},{"key":"804_CR48","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"804_CR49","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/ana.10517","volume":"53","author":"JL Vitek","year":"2003","unstructured":"Vitek, J. L. et al. Randomized trial of pallidotomy versus medical therapy for Parkinson\u2019s disease. Ann. Neurol. 53, 558\u2013569 (2003).","journal-title":"Ann. Neurol."},{"key":"804_CR50","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ana.410400305","volume":"40","author":"MS Baron","year":"1996","unstructured":"Baron, M. S. et al. Treatment of advanced Parkinson\u2019s disease by posterior GPi pallidotomy: 1-year results of a pilot study. Ann. Neurol. 40, 355\u2013366 (1996).","journal-title":"Ann. Neurol."},{"key":"804_CR51","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1056\/NEJM199710093371503","volume":"337","author":"AE Lang","year":"1997","unstructured":"Lang, A. E. et al. Posteroventral medial pallidotomy in advanced Parkinson\u2019s disease. N. Engl. J. Med. 337, 1036\u20131043 (1997).","journal-title":"N. Engl. J. Med."},{"key":"804_CR52","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/1531-8257(200101)16:1<72::AID-MDS1019>3.0.CO;2-6","volume":"16","author":"L Alvarez","year":"2001","unstructured":"Alvarez, L. et al. Dorsal subthalamotomy for Parkinson\u2019s disease. Mov. Disord. 16, 72\u201378 (2001).","journal-title":"Mov. Disord."},{"key":"804_CR53","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S0140-6736(05)63455-1","volume":"350","author":"P Heywood","year":"1997","unstructured":"Heywood, P. & Gill, S. S. Bilateral dorsolateral subthalamotomy for advanced Parkinson\u2019s disease. Lancet 350, 1224 (1997).","journal-title":"Lancet"},{"key":"804_CR54","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/jgm.1100","volume":"9","author":"ML Edelstein","year":"2007","unstructured":"Edelstein, M. L., Abedi, M. R. & Wixon, J. Gene therapy clinical trials worldwide to 2007\u2014an update. J. Gene Med. 9, 833\u2013842 (2007).","journal-title":"J. Gene Med."},{"key":"804_CR55","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","volume":"70","author":"JL Eberling","year":"2008","unstructured":"Eberling, J. L. et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70, 1980\u20131983 (2008).","journal-title":"Neurology"},{"key":"804_CR56","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","volume":"73","author":"CW Christine","year":"2009","unstructured":"Christine, C. W. et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73, 1662\u20131669 (2009).","journal-title":"Neurology"},{"key":"804_CR57","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.25450","volume":"85","author":"CW Christine","year":"2019","unstructured":"Christine, C. W. et al. Magnetic resonance imaging\u2013guided phase 1 trial of putaminal AADC gene therapy for Parkinson\u2019s disease. Ann. Neurol. 85, 704\u2013714 (2019).","journal-title":"Ann. Neurol."},{"key":"804_CR58","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1212\/WNL.0000000000012952","volume":"98","author":"CW Christine","year":"2022","unstructured":"Christine, C. W. et al. Safety of AADC gene therapy for moderately advanced Parkinson disease. Neurology 98, e40\u2013e50 (2022).","journal-title":"Neurology"},{"key":"804_CR59","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","volume":"383","author":"S Palfi","year":"2014","unstructured":"Palfi, S. et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson\u2019s disease: a dose escalation, open-label, phase 1\/2 trial. Lancet 383, 1138\u20131146 (2014).","journal-title":"Lancet"},{"key":"804_CR60","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1089\/humc.2018.081","volume":"29","author":"S Palfi","year":"2018","unstructured":"Palfi, S. et al. Long-term follow-up of a phase I\/II study of ProSavin, a lentiviral vector gene therapy for Parkinson\u2019s disease. Hum. Gene Ther. Clin. Dev. 29, 148\u2013155 (2018).","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"804_CR61","unstructured":"Plc, O. B. Oxford Biomedica announces update to agreement with Sio Gene Therapies. GlobeNewswire News Room https:\/\/www.globenewswire.com\/news-release\/2022\/01\/31\/2376128\/0\/en\/Oxford-Biomedica-announces-update-to-agreement-with-Sio-Gene-Therapies.html (2022)."},{"key":"804_CR62","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/BF00711302","volume":"7","author":"DL Martin","year":"1987","unstructured":"Martin, D. L. Regulatory properties of brain glutamate decarboxylase. Cell Mol. Neurobiol. 7, 237\u2013253 (1987).","journal-title":"Cell Mol. Neurobiol."},{"key":"804_CR63","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/brain\/awh029","volume":"127","author":"C Hamani","year":"2004","unstructured":"Hamani, C., Saint\u2010Cyr, J. A., Fraser, J., Kaplitt, M. & Lozano, A. M. The subthalamic nucleus in the context of movement disorders. Brain 127, 4\u201320 (2004).","journal-title":"Brain"},{"key":"804_CR64","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","volume":"369","author":"MG Kaplitt","year":"2007","unstructured":"Kaplitt, M. G. et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson\u2019s disease: an open label, phase I trial. Lancet 369, 2097\u20132105 (2007).","journal-title":"Lancet"},{"key":"804_CR65","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","volume":"10","author":"PA LeWitt","year":"2011","unstructured":"LeWitt, P. A. et al. AAV2-GAD gene therapy for advanced Parkinson\u2019s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 10, 309\u2013319 (2011).","journal-title":"Lancet Neurol."},{"key":"804_CR66","doi-asserted-by":"publisher","unstructured":"Salomonsson, S. E. & Clelland, C. D. Building CRISPR gene therapies for the central nervous system: a review. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2023.4983 (2024).","DOI":"10.1001\/jamaneurol.2023.4983"},{"key":"804_CR67","doi-asserted-by":"publisher","unstructured":"Reardon, S. First CRISPR clinical trial gets green light from US panel. Nature https:\/\/doi.org\/10.1038\/nature.2016.20137 (2016).","DOI":"10.1038\/nature.2016.20137"},{"key":"804_CR68","doi-asserted-by":"publisher","unstructured":"Kim, Y. J. et al. Magnetoelectric nanodiscs enable wireless transgene-free neuromodulation https:\/\/doi.org\/10.1101\/2023.12.24.573272 (2023).","DOI":"10.1101\/2023.12.24.573272"},{"key":"804_CR69","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3390\/pharmaceutics12080752","volume":"12","author":"N Carballo-Pedrares","year":"2020","unstructured":"Carballo-Pedrares, N., Fuentes-Boquete, I., D\u00edaz-Prado, S. & Rey-Rico, A. Hydrogel-based localized nonviral gene delivery in regenerative medicine approaches\u2014an overview. Pharmaceutics 12, 752 (2020).","journal-title":"Pharmaceutics"},{"key":"804_CR70","doi-asserted-by":"crossref","unstructured":"Chen, J., Guo, Z., Tian, H. & Chen, X. Production and clinical development of nanoparticles for gene delivery. Mol. Ther. Methods Clin. Dev. 3, 1\u20138 (2016).","DOI":"10.1038\/mtm.2016.23"},{"key":"804_CR71","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMc2300400","volume":"389","author":"P McColgan","year":"2023","unstructured":"McColgan, P. et al. Tominersen in adults with manifest Huntington\u2019s disease. N. Engl. J. Med. 389, 2203\u20132205 (2023).","journal-title":"N. Engl. J. Med."},{"key":"804_CR72","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41551-021-00829-3","volume":"7","author":"A Bansal","year":"2023","unstructured":"Bansal, A., Shikha, S. & Zhang, Y. Towards translational optogenetics. Nat. Biomed. Eng. 7, 349\u2013369 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"804_CR73","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nature09159","volume":"466","author":"AV Kravitz","year":"2010","unstructured":"Kravitz, A. V. et al. Regulation of Parkinsonian motor behaviors by optogenetic control of basal ganglia circuitry. Nature 466, 622\u2013626 (2010).","journal-title":"Nature"},{"key":"804_CR74","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nn.4559","volume":"20","author":"KJ Mastro","year":"2017","unstructured":"Mastro, K. J. et al. Cell-specific pallidal intervention induces long-lasting motor recovery in dopamine-depleted mice. Nat. Neurosci. 20, 815\u2013823 (2017).","journal-title":"Nat. Neurosci."},{"key":"804_CR75","doi-asserted-by":"publisher","first-page":"7855","DOI":"10.1523\/JNEUROSCI.0361-20.2020","volume":"40","author":"A Pamukcu","year":"2020","unstructured":"Pamukcu, A. et al. Parvalbumin + and Npas1 + pallidal neurons have distinct circuit topology and function. J. Neurosci. 40, 7855\u20137876 (2020).","journal-title":"J. Neurosci."},{"key":"804_CR76","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1126\/science.1167093","volume":"324","author":"V Gradinaru","year":"2009","unstructured":"Gradinaru, V., Mogri, M., Thompson, K. R., Henderson, J. M. & Deisseroth, K. Optical deconstruction of Parkinsonian neural circuitry. Science 324, 354\u2013359 (2009).","journal-title":"Science"},{"key":"804_CR77","doi-asserted-by":"publisher","first-page":"10380","DOI":"10.1523\/JNEUROSCI.3863-06.2006","volume":"26","author":"K Deisseroth","year":"2006","unstructured":"Deisseroth, K. et al. Next-generation optical technologies for illuminating genetically targeted brain circuits. J. Neurosci. 26, 10380\u201310386 (2006).","journal-title":"J. Neurosci."},{"key":"804_CR78","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1523\/JNEUROSCI.3071-19.2020","volume":"40","author":"C Yu","year":"2020","unstructured":"Yu, C., Cassar, I. R., Sambangi, J. & Grill, W. M. Frequency-specific optogenetic deep brain stimulation of subthalamic nucleus improves Parkinsonian motor behaviors. J. Neurosci. 40, 4323\u20134334 (2020).","journal-title":"J. Neurosci."},{"key":"804_CR79","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/nmeth.3536","volume":"12","author":"KL Montgomery","year":"2015","unstructured":"Montgomery, K. L. et al. Wirelessly powered, fully internal optogenetics for brain, spinal and peripheral circuits in mice. Nat. Methods 12, 969\u2013974 (2015).","journal-title":"Nat. Methods"},{"key":"804_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20803-y","volume":"12","author":"CY Kim","year":"2021","unstructured":"Kim, C. Y. et al. Soft subdermal implant capable of wireless battery charging and programmable controls for applications in optogenetics. Nat. Commun. 12, 535 (2021).","journal-title":"Nat. Commun."},{"key":"804_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201700446","volume":"6","author":"X Lin","year":"2017","unstructured":"Lin, X. et al. Multiplexed optogenetic stimulation of neurons with spectrum-selective upconversion nanoparticles. Adv. Healthc. Mater. 6, 1700446 (2017).","journal-title":"Adv. Healthc. Mater."},{"key":"804_CR82","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1126\/science.aaq1144","volume":"359","author":"S Chen","year":"2018","unstructured":"Chen, S. et al. Near-infrared deep brain stimulation via upconversion nanoparticle-mediated optogenetics. Science 359, 679\u2013684 (2018).","journal-title":"Science"},{"key":"804_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25993-7","volume":"12","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. Near-infrared manipulation of multiple neuronal populations via trichromatic upconversion. Nat. Commun. 12, 5662 (2021).","journal-title":"Nat. Commun."},{"key":"804_CR84","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1126\/science.1261821","volume":"347","author":"R Chen","year":"2015","unstructured":"Chen, R., Romero, G., Christiansen, M. G., Mohr, A. & Anikeeva, P. Wireless magnetothermal deep brain stimulation. Science 347, 1477\u20131480 (2015).","journal-title":"Science"},{"key":"804_CR85","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.27069","volume":"6","author":"R Munshi","year":"2017","unstructured":"Munshi, R. et al. Magnetothermal genetic deep brain stimulation of motor behaviors in awake, freely moving mice. eLife 6, e27069 (2017).","journal-title":"eLife"},{"key":"804_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25837-4","volume":"12","author":"S-A Hescham","year":"2021","unstructured":"Hescham, S.-A. et al. Magnetothermal nanoparticle technology alleviates Parkinsonian-like symptoms in mice. Nat. Commun. 12, 5569 (2021).","journal-title":"Nat. Commun."},{"key":"804_CR87","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.neuron.2020.05.019","volume":"107","author":"A Singer","year":"2020","unstructured":"Singer, A. et al. Magnetoelectric materials for miniature, wireless neural stimulation at therapeutic frequencies. Neuron 107, 631\u2013643.e5 (2020).","journal-title":"Neuron"},{"key":"804_CR88","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.2217\/nnm.15.52","volume":"10","author":"R Guduru","year":"2015","unstructured":"Guduru, R. et al. Magnetoelectric \u2018spin\u2019 on stimulating the brain. Nanomedicine 10, 2051\u20132061 (2015).","journal-title":"Nanomedicine"},{"key":"804_CR89","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1007\/s13311-021-01071-0","volume":"18","author":"T Nguyen","year":"2021","unstructured":"Nguyen, T. et al. In vivo wireless brain stimulation via non-invasive and targeted delivery of magnetoelectric nanoparticles. Neurotherapeutics 18, 2091\u20132106 (2021).","journal-title":"Neurotherapeutics"},{"key":"804_CR90","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc4189","volume":"7","author":"KL Kozielski","year":"2021","unstructured":"Kozielski, K. L. et al. Nonresonant powering of injectable nanoelectrodes enables wireless deep brain stimulation in freely moving mice. Sci. Adv. 7, eabc4189 (2021).","journal-title":"Sci. Adv."},{"key":"804_CR91","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1021\/acs.nanolett.6b03517","volume":"17","author":"RD Airan","year":"2017","unstructured":"Airan, R. D. et al. Noninvasive targeted transcranial neuromodulation via focused ultrasound gated drug release from nanoemulsions. Nano Lett. 17, 652\u2013659 (2017).","journal-title":"Nano Lett."},{"key":"804_CR92","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.neuron.2018.10.042","volume":"100","author":"JB Wang","year":"2018","unstructured":"Wang, J. B., Aryal, M., Zhong, Q., Vyas, D. B. & Airan, R. D. Noninvasive ultrasonic drug uncaging maps whole-brain functional networks. Neuron 100, 728\u2013738.e7 (2018).","journal-title":"Neuron"},{"key":"804_CR93","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jconrel.2021.02.010","volume":"332","author":"H Lea-Banks","year":"2021","unstructured":"Lea-Banks, H. et al. Ultrasound-sensitive nanodroplets achieve targeted neuromodulation. J. Control. Release 332, 30\u201339 (2021).","journal-title":"J. Control. Release"},{"key":"804_CR94","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41551-022-00965-4","volume":"7","author":"T Kim","year":"2023","unstructured":"Kim, T. et al. Deep brain stimulation by blood\u2013brain-barrier-crossing piezoelectric nanoparticles generating current and nitric oxide under focused ultrasound. Nat. Biomed. Eng. 7, 149\u2013163 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"804_CR95","doi-asserted-by":"publisher","first-page":"808","DOI":"10.3762\/bjnano.12.64","volume":"12","author":"S Tehrani Fateh","year":"2021","unstructured":"Tehrani Fateh, S., Moradi, L., Kohan, E., Hamblin, M. R. & Shiralizadeh Dezfuli, A. Comprehensive review on ultrasound-responsive theranostic nanomaterials: mechanisms, structures and medical applications. Beilstein J. Nanotechnol. 12, 808\u2013862 (2021).","journal-title":"Beilstein J. Nanotechnol."},{"key":"804_CR96","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1073\/pnas.0700293104","volume":"104","author":"BN Armbruster","year":"2007","unstructured":"Armbruster, B. N., Li, X., Pausch, M. H., Herlitze, S. & Roth, B. L. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc. Natl Acad. Sci. 104, 5163\u20135168 (2007).","journal-title":"Proc. Natl Acad. Sci."},{"key":"804_CR97","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neuron.2009.06.014","volume":"63","author":"GM Alexander","year":"2009","unstructured":"Alexander, G. M. et al. Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron 63, 27\u201339 (2009).","journal-title":"Neuron"},{"key":"804_CR98","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1172\/JCI74664","volume":"124","author":"MT Dell\u2019Anno","year":"2014","unstructured":"Dell\u2019Anno, M. T. et al. Remote control of induced dopaminergic neurons in parkinsonian rats. J. Clin. Invest. 124, 3215\u20133229 (2014).","journal-title":"J. Clin. Invest."},{"key":"804_CR99","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1172\/JCI90132","volume":"127","author":"C Alcacer","year":"2017","unstructured":"Alcacer, C. et al. Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson\u2019s disease therapy. J. Clin. Invest. 127, 720\u2013734 (2017).","journal-title":"J. Clin. Invest."},{"key":"804_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2019.03.002","volume":"177","author":"M Roet","year":"2019","unstructured":"Roet, M. et al. Progress in neuromodulation of the brain: a role for magnetic nanoparticles? Prog. Neurobiol. 177, 1\u201314 (2019).","journal-title":"Prog. Neurobiol."},{"key":"804_CR101","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1126\/science.aan2475","volume":"357","author":"JL Gomez","year":"2017","unstructured":"Gomez, J. L. et al. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine. Science 357, 503\u2013507 (2017).","journal-title":"Science"},{"key":"804_CR102","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s41593-020-0661-3","volume":"23","author":"Y Nagai","year":"2020","unstructured":"Nagai, Y. et al. Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys. Nat. Neurosci. 23, 1157\u20131167 (2020).","journal-title":"Nat. Neurosci."},{"key":"804_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12236-z","volume":"10","author":"J Bonaventura","year":"2019","unstructured":"Bonaventura, J. et al. High-potency ligands for DREADD imaging and activation in rodents and monkeys. Nat. Commun. 10, 4627 (2019).","journal-title":"Nat. Commun."},{"key":"804_CR104","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nn.4192","volume":"19","author":"MAG Eldridge","year":"2016","unstructured":"Eldridge, M. A. G. et al. Chemogenetic disconnection of monkey orbitofrontal and rhinal cortex reversibly disrupts reward value. Nat. Neurosci. 19, 37\u201339 (2016).","journal-title":"Nat. Neurosci."},{"key":"804_CR105","doi-asserted-by":"publisher","first-page":"105980","DOI":"10.1016\/j.parkreldis.2023.105980","volume":"121","author":"F Cavallieri","year":"2024","unstructured":"Cavallieri, F., Mulroy, E. & Moro, E. The history of deep brain stimulation. Parkinsonism Relat. Disord. 121, 105980 (2024).","journal-title":"Parkinsonism Relat. Disord."},{"key":"804_CR106","first-page":"658083","volume":"2011","author":"JA Potashkin","year":"2010","unstructured":"Potashkin, J. A., Blume, S. R. & Runkle, N. K. Limitations of animal models of Parkinson\u2019s disease. Parkinsons Dis. 2011, 658083 (2010).","journal-title":"Parkinsons Dis."},{"key":"804_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48731-1","volume":"15","author":"N Rajamani","year":"2024","unstructured":"Rajamani, N. et al. Deep brain stimulation of symptom-specific networks in Parkinson\u2019s disease. Nat. Commun. 15, 4662 (2024).","journal-title":"Nat. Commun."},{"key":"804_CR108","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jns.2013.07.005","volume":"332","author":"D Santos-Garc\u00eda","year":"2013","unstructured":"Santos-Garc\u00eda, D. & de la Fuente-Fern\u00e1ndez, R. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson\u2019s disease. J. Neurol. Sci. 332, 136\u2013140 (2013).","journal-title":"J. Neurol. Sci."},{"key":"804_CR109","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.parkreldis.2013.07.010","volume":"19","author":"B M\u00fcller","year":"2013","unstructured":"M\u00fcller, B., Assmus, J., Herlofson, K., Larsen, J. P. & Tysnes, O.-B. Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson\u2019s disease. Parkinsonism Relat. Disord. 19, 1027\u20131032 (2013).","journal-title":"Parkinsonism Relat. Disord."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00804-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00804-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00804-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T18:04:57Z","timestamp":1729706697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00804-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":109,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["804"],"URL":"https:\/\/doi.org\/10.1038\/s41531-024-00804-0","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"31 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.D.C. and J.K.W. declare no financial or non-financial competing interests. A.D.C.\u2019s fellowship is supported by the Davis Rembert Family Foundation. J.K.W.\u2019s research is supported by NIH KL2TR001429. MSO serves as Medical Advisor the Parkinson\u2019s Foundation, and has received research grants from NIH, Parkinson\u2019s Foundation, the Michael J. Fox Foundation, the Parkinson Alliance, Smallwood Foundation, the Bachmann-Strauss Foundation, the Tourette Syndrome Association, and the UF Foundation. MSO\u2019s research is supported by: R01 NS131342 NIH R01 NR014852, R01NS096008, UH3NS119844, U01NS119562. MSO is PI of the NIH R25NS108939 Training Grant. M.S.O. has received royalties for publications with Hachette Book Group, Demos, Manson, Amazon, Smashwords, Books4Patients, Perseus, Robert Rose, Oxford and Cambridge (movement disorders books). M.S.O. is an associate editor for New England Journal of Medicine Journal Watch Neurology and JAMA Neurology. M.S.O. has participated in CME and educational activities (past 12-24 months) on movement disorders sponsored by WebMD\/Medscape, RMEI Medical Education, American Academy of Neurology, Movement Disorders Society, Mediflix and by Vanderbilt University. The institution and not MSO receives grants from industry. M.S.O. has participated as a site PI and\/or co-I for several NIH, foundation, and industry sponsored trials over the years but has not received honoraria. Research projects at the University of Florida receive device and drug donations.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"195"}}